Q1 Earnings Forecast for ABEO Issued By Zacks Small Cap

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Equities researchers at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Abeona Therapeutics in a research note issued to investors on Monday, March 24th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will earn ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics' Q2 2025 earnings at ($0.33) EPS.

Other analysts have also recently issued reports about the stock. StockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, March 24th. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They set an "outperform" rating and a $16.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Abeona Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $17.50.

Remove Ads

Abeona Therapeutics Stock Performance

Shares of ABEO stock traded down $0.07 during trading hours on Wednesday, reaching $4.97. 529,297 shares of the company traded hands, compared to its average volume of 408,282. The firm has a 50-day moving average price of $5.42 and a 200 day moving average price of $5.81. The company has a market cap of $241.21 million, a P/E ratio of -1.85 and a beta of 1.79. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $8.45. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.19.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ABEO. Jane Street Group LLC purchased a new stake in Abeona Therapeutics during the third quarter valued at $84,000. JPMorgan Chase & Co. raised its position in shares of Abeona Therapeutics by 74.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock valued at $424,000 after buying an additional 28,606 shares in the last quarter. Western Standard LLC lifted its holdings in shares of Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company's stock valued at $10,732,000 after acquiring an additional 110,998 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new position in Abeona Therapeutics in the third quarter worth about $151,000. Finally, XTX Topco Ltd bought a new stake in Abeona Therapeutics during the third quarter worth approximately $160,000. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.